Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1992 Feb 1;89(3):1085–1089. doi: 10.1073/pnas.89.3.1085

Tamoxifen prevents induction of hepatic neoplasia by zeranol, an estrogenic food contaminant.

J E Coe 1, K G Ishak 1, J M Ward 1, M J Ross 1
PMCID: PMC48390  PMID: 1736291

Abstract

Zeranol (alpha-zearalanol) is a beta-resorcylic acid lactone (RAL) that has estrogen activity. It is synthesized by molds and is difficult to avoid in human food products. We tested the ability of this mycoestrogen to damage the liver of the Armenian hamster, a rodent that is especially sensitive to hepatotoxic effects of exogenous estrogens. Zeranol induced acute hepatotoxicity and, subsequently, hepatic carcinogenesis; both effects were blocked by tamoxifen, suggesting estrogen receptor mediation. Because zeranol is acting alone as a primary initiator of hepatic neoplasms, this model provides an unusual opportunity to study the pathogenesis of estrogen-initiated tumorigenesis.

Full text

PDF
1085

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aten R. F., Weinberger M. J., Eisenfeld A. J. Estrogen receptor in rat liver: translocation to the nucleus in vivo. Endocrinology. 1978 Feb;102(2):433–442. doi: 10.1210/endo-102-2-433. [DOI] [PubMed] [Google Scholar]
  2. Bannasch P. Pathobiology of chemical hepatocarcinogenesis: recent progress and perspectives. Part I. Cytomorphological changes and cell proliferation. J Gastroenterol Hepatol. 1990 Mar-Apr;5(2):149–159. doi: 10.1111/j.1440-1746.1990.tb01820.x. [DOI] [PubMed] [Google Scholar]
  3. Baum J. K., Bookstein J. J., Holtz F., Klein E. W. Possible association between benign hepatomas and oral contraceptives. Lancet. 1973 Oct 27;2(7835):926–929. doi: 10.1016/s0140-6736(73)92594-4. [DOI] [PubMed] [Google Scholar]
  4. Beers P. C., Rosner W. The binding of estrogens in the liver of the rat: demonstration and endocrine influences. J Steroid Biochem. 1977 Apr;8(4):251–258. doi: 10.1016/0022-4731(77)90017-6. [DOI] [PubMed] [Google Scholar]
  5. Cadrin M., Kawahara H., Ohta M., Katsuma Y., Marceau N., French S. W. Mallory bodies in hepatomas and hyperplastic nodules: in vitro and in vivo studies. Prog Clin Biol Res. 1990;331:231–248. [PubMed] [Google Scholar]
  6. Chamness G. C., Costlow M. E., McGuire W. L. Estrogen receptor in rat liver and its dependence on prolactin. Steroids. 1975 Sep;26(3):363–371. doi: 10.1016/0039-128x(75)90081-1. [DOI] [PubMed] [Google Scholar]
  7. Coe J. E., Ishak K. G., Ross M. J. Diethylstilbestrol-induced jaundice in the Chinese and Armenian hamster. Hepatology. 1983 Jul-Aug;3(4):489–496. doi: 10.1002/hep.1840030404. [DOI] [PubMed] [Google Scholar]
  8. Coe J. E., Ishak K. G., Ross M. J. Estrogen induction of hepatocellular carcinomas in Armenian hamsters. Hepatology. 1990 Apr;11(4):570–577. doi: 10.1002/hep.1840110408. [DOI] [PubMed] [Google Scholar]
  9. Coe J. E., Ross M. J. Amyloidosis and female protein in the Syrian hamster. Concurrent regulation by sex hormones. J Exp Med. 1990 Apr 1;171(4):1257–1267. doi: 10.1084/jem.171.4.1257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Coe J. E., Ross M. J. Armenian hamster female protein: a pentraxin under complex regulation. Am J Physiol. 1990 Aug;259(2 Pt 2):R341–R349. doi: 10.1152/ajpregu.1990.259.2.R341. [DOI] [PubMed] [Google Scholar]
  11. Coe J. E., Ross M. J. Tamoxifen inhibits estrogen-induced hepatic injury in hamsters. Endocrinology. 1988 Jan;122(1):137–144. doi: 10.1210/endo-122-1-137. [DOI] [PubMed] [Google Scholar]
  12. Denk H., Gschnait F., Wolff K. Hepatocellar hyalin (Mallory bodies) in long term griseofulvin-treated mice: a new experimental model for the study of hyalin formation. Lab Invest. 1975 Jun;32(6):773–776. [PubMed] [Google Scholar]
  13. Dragan Y. P., Xu Y. D., Pitot H. C. Tumor promotion as a target for estrogen/antiestrogen effects in rat hepatocarcinogenesis. Prev Med. 1991 Jan;20(1):15–26. doi: 10.1016/0091-7435(91)90003-m. [DOI] [PubMed] [Google Scholar]
  14. Edmondson H. A., Henderson B., Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med. 1976 Feb 26;294(9):470–472. doi: 10.1056/NEJM197602262940904. [DOI] [PubMed] [Google Scholar]
  15. Farber E., Sarma D. S. Hepatocarcinogenesis: a dynamic cellular perspective. Lab Invest. 1987 Jan;56(1):4–22. [PubMed] [Google Scholar]
  16. Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990 Jun 1;61(5):759–767. doi: 10.1016/0092-8674(90)90186-i. [DOI] [PubMed] [Google Scholar]
  17. Forman D., Vincent T. J., Doll R. Cancer of the liver and the use of oral contraceptives. Br Med J (Clin Res Ed) 1986 May 24;292(6532):1357–1361. doi: 10.1136/bmj.292.6532.1357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Frith C. H., Ward J. M. A morphologic classification of proliferative and neoplastic hepatic lesions in mice. J Environ Pathol Toxicol. 1979 Dec;3(1-2):329–351. [PubMed] [Google Scholar]
  19. Furr B. J., Jordan V. C. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther. 1984;25(2):127–205. doi: 10.1016/0163-7258(84)90043-3. [DOI] [PubMed] [Google Scholar]
  20. Henderson B. E., Preston-Martin S., Edmondson H. A., Peters R. L., Pike M. C. Hepatocellular carcinoma and oral contraceptives. Br J Cancer. 1983 Sep;48(3):437–440. doi: 10.1038/bjc.1983.210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Herbst A. L., Ulfelder H., Poskanzer D. C. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971 Apr 15;284(15):878–881. doi: 10.1056/NEJM197104222841604. [DOI] [PubMed] [Google Scholar]
  22. Hertz R. A review of the evidence linking estrogens and cancer in animals. Pediatrics. 1978 Dec;62(6 Pt 2):1138–1142. [PubMed] [Google Scholar]
  23. Hoso M., Nakanuma Y. Clinicopathological characteristics of hepatocellular carcinoma bearing Mallory bodies: an autopsy study. Liver. 1990 Oct;10(5):264–268. doi: 10.1111/j.1600-0676.1990.tb00468.x. [DOI] [PubMed] [Google Scholar]
  24. Jordan V. C., Lababidi M. K., Langan-Fahey S. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst. 1991 Apr 3;83(7):492–496. doi: 10.1093/jnci/83.7.492. [DOI] [PubMed] [Google Scholar]
  25. Katzenellenbogen B. S., Katzenellenbogen J. A., Mordecai D. Zearalenones: characterization of the estrogenic potencies and receptor interactions of a series of fungal beta-resorcylic acid lactones. Endocrinology. 1979 Jul;105(1):33–40. doi: 10.1210/endo-105-1-33. [DOI] [PubMed] [Google Scholar]
  26. Kuiper-Goodman T., Scott P. M., Watanabe H. Risk assessment of the mycotoxin zearalenone. Regul Toxicol Pharmacol. 1987 Sep;7(3):253–306. doi: 10.1016/0273-2300(87)90037-7. [DOI] [PubMed] [Google Scholar]
  27. Lam H. Y. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun. 1984 Jan 13;118(1):27–32. doi: 10.1016/0006-291x(84)91062-3. [DOI] [PubMed] [Google Scholar]
  28. Lindsay D. G. Zeranol--a 'nature-identical' oestrogen? Food Chem Toxicol. 1985 Aug;23(8):767–774. doi: 10.1016/0278-6915(85)90273-x. [DOI] [PubMed] [Google Scholar]
  29. Lippman M. E., Dickson R. B. Mitogenic regulation of normal and malignant breast epithelium. Yale J Biol Med. 1989 Sep-Oct;62(5):459–480. [PMC free article] [PubMed] [Google Scholar]
  30. Lipsett M. B. Hormones, medications, and cancer. Cancer. 1983 Jun 15;51(12 Suppl):2426–2429. doi: 10.1002/1097-0142(19830615)51:12+<2426::aid-cncr2820511307>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  31. Mays E. T., Christopherson W. Hepatic tumors induced by sex steroids. Semin Liver Dis. 1984 May;4(2):147–157. doi: 10.1055/s-2008-1040654. [DOI] [PubMed] [Google Scholar]
  32. Nelson K. G., Takahashi T., Bossert N. L., Walmer D. K., McLachlan J. A. Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation. Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):21–25. doi: 10.1073/pnas.88.1.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Neuberger J., Forman D., Doll R., Williams R. Oral contraceptives and hepatocellular carcinoma. Br Med J (Clin Res Ed) 1986 May 24;292(6532):1355–1357. doi: 10.1136/bmj.292.6532.1355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. O'Brian C. A., Liskamp R. M., Solomon D. H., Weinstein I. B. Triphenylethylenes: a new class of protein kinase C inhibitors. J Natl Cancer Inst. 1986 Jun;76(6):1243–1246. [PubMed] [Google Scholar]
  35. Popper H., Shafritz D. A., Hoofnagle J. H. Relation of the hepatitis B virus carrier state to hepatocellular carcinoma. Hepatology. 1987 Jul-Aug;7(4):764–772. doi: 10.1002/hep.1840070425. [DOI] [PubMed] [Google Scholar]
  36. Powell-Jones W., Davies P., Griffiths K. Specific binding of (3H) oestradiol by cytoplasmic protein components of female rat liver. J Endocrinol. 1976 Apr;69(1):167–168. doi: 10.1677/joe.0.0690167. [DOI] [PubMed] [Google Scholar]
  37. Powell-Jones W., Nayfeh S. N., Lucier G. W. Translocation of 4S and 5S forms of estrogen-receptors into rat liver nuclei in vitro. Biochem Biophys Res Commun. 1978 Nov 14;85(1):167–173. doi: 10.1016/s0006-291x(78)80025-4. [DOI] [PubMed] [Google Scholar]
  38. Powell-Jones W., Raeford S., Lucier G. W. Binding properties of zearalenone mycotoxins to hepatic estrogen receptors. Mol Pharmacol. 1981 Jul;20(1):35–42. [PubMed] [Google Scholar]
  39. Rooks J. B., Ory H. W., Ishak K. G., Strauss L. T., Greenspan J. R., Hill A. P., Tyler C. W., Jr Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA. 1979 Aug 17;242(7):644–648. [PubMed] [Google Scholar]
  40. Schechter A. L., Stern D. F., Vaidyanathan L., Decker S. J., Drebin J. A., Greene M. I., Weinberg R. A. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984 Dec 6;312(5994):513–516. doi: 10.1038/312513a0. [DOI] [PubMed] [Google Scholar]
  41. Schoental R. Trichothecenes, zearalenone, and other carcinogenic metabolites of Fusarium and related microfungi. Adv Cancer Res. 1985;45:217–290. doi: 10.1016/s0065-230x(08)60270-5. [DOI] [PubMed] [Google Scholar]
  42. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707–712. doi: 10.1126/science.2470152. [DOI] [PubMed] [Google Scholar]
  43. Weinstein I. B. The origins of human cancer: molecular mechanisms of carcinogenesis and their implications for cancer prevention and treatment--twenty-seventh G.H.A. Clowes memorial award lecture. Cancer Res. 1988 Aug 1;48(15):4135–4143. [PubMed] [Google Scholar]
  44. Yager J. D., Shi Y. E. Synthetic estrogens and tamoxifen as promoters of hepatocarcinogenesis. Prev Med. 1991 Jan;20(1):27–37. doi: 10.1016/0091-7435(91)90004-n. [DOI] [PubMed] [Google Scholar]
  45. Yokoo H., Harwood T. R., Racker D., Arak S. Experimental production of Mallory bodies in mice by diet containing 3,5-diethoxycarbonyl-1,4-dihydrocollidine. Gastroenterology. 1982 Jul;83(1 Pt 1):109–113. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES